Lower cholesterol levels are associated with worse outcomes in patients with chronic heart failure (HF) and have been shown to predict in-hospital mortality. The relation between lipid profile and postdischarge outcomes in patients hospitalized for worsening HF is less clear. In this post hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), 3,957 patients hospitalized for worsening HF with ejection fractions ≤40% were examined. Baseline total cholesterol and triglyceride levels were measured
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Authors: Greene, Stephen J SJ; Vaduganathan, Muthiah M; Lupi, Laura L; Ambrosy, Andrew P AP; Mentz, Robert J RJ; Konstam, Marvin A MA; Nodari, Savina S; Subacius, Haris P HP; Fonarow, Gregg C GC; Bonow, Robert O RO; Gheorghiade, Mihai M;
The American journal of cardiology. 2013 Feb 15;111(4):574-81. Epub 2012-12-01.